Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis

Einar Heldal
European Respiratory Journal 2017 50: 1701696; DOI: 10.1183/13993003.01696-2017
Einar Heldal
Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: einar.heldal@gmail.com
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis http://ow.ly/18cd30fiJfs

From the authors:

We thank D. Chesov and co-workers for sharing data on isoniazid-resistant strains in Moldova as a comment on our paper on shorter regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) [1]. In strains from MDR-TB patients, a high proportion (88%) had a mutation in the katG gene at position 315, results which “…strongly suggest that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB…”, based on the “…general consensus that high-level isoniazid resistance due to a mutation in the katG gene at position 315 cannot be overcome by high-dose isoniazid treatment…”. They refer to a recent TBNET/RESIST-TB consensus statement [2] which says that molecular testing for isoniazid resistance should be done since “…it offers the possibility to add INH to a second-line drug regimen in the absence of a katG 315 mutation…”.

We do not agree with this conclusion because there are a number of studies, discussed by amongst others Rieder et al. [3] and Otto-Knapp et al. [4], which compare genotypic and phenotypic drug-susceptibility testing results, and which indicate that strains with this mutation have highly variable minimum inhibitory concentrations and that a majority of strains with low or moderate-level resistance can be effectively treated with isoniazid at normal or high doses. Finding this mutation should not therefore be the sole reason for exclusion of isoniazid from the treatment regimen. Indeed, a previous TBNET consensus statement recommended that dosing of isoniazid should be adjusted according to the minimum inhibitory concentration test results whenever possible [5]. Furthermore, the shortened regimen no longer counts on high-dose isoniazid as a major drug but only as a less toxic companion, since full susceptibility was not expected in the original design [6].

Footnotes

  • Conflict of interest: None declared.

  • Received August 19, 2017.
  • Accepted August 21, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Heldal E,
    2. Van Deun A,
    3. Chiang C-Y
    , et al. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe. Eur Respir J 2017; 49: 1700228.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Dominguez J,
    2. Boettger EC,
    3. Cirillo D
    , et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rieder HL,
    2. Van Deun A
    . Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2017; 21: 123–124.
    OpenUrl
  4. ↵
    1. Otto-Knapp R,
    2. Vesenbeckh S,
    3. Schönfeld N
    , et al. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. Int J Tuberc Lung Dis 2016; 20: 1275–1276.
    OpenUrl
  5. ↵
    1. Lange C,
    2. Abubakar I,
    3. Alffenaar JW
    , et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23–63.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Van Deun A,
    2. Chiang C-Y
    . Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance. Eur Respir J 2017; 49: 1700223.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 4 Table of Contents
European Respiratory Journal: 50 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis
Einar Heldal
European Respiratory Journal Oct 2017, 50 (4) 1701696; DOI: 10.1183/13993003.01696-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis
Einar Heldal
European Respiratory Journal Oct 2017, 50 (4) 1701696; DOI: 10.1183/13993003.01696-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • NTM-PD incidence among elderly patients with bronchiectasis
  • Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Reply: Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
Show more Agora

Correspondence

  • Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Reply: Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Reply: Radiomics in ILD associated with systemic sclerosis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society